[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5462627f1bc001d8b588a09ab9f4174caec1066815d0c59b05dd91fb4469e1be",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751992860,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 135861841,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5462627f1bc001d8b588a09ab9f4174caec1066815d0c59b05dd91fb4469e1be"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?",
    "summary": "AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?",
    "url": "https://finnhub.io/api/news?id=4a4d2e484a5783d48b9c3ae552230dc702f6db466a214e2a91302d00d3ef90c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751985780,
      "headline": "AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?",
      "id": 135811706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?",
      "url": "https://finnhub.io/api/news?id=4a4d2e484a5783d48b9c3ae552230dc702f6db466a214e2a91302d00d3ef90c3"
    }
  },
  {
    "ts": null,
    "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751981508,
      "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "id": 135854926,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6"
    }
  },
  {
    "ts": null,
    "headline": "June Readers Tagged 13 Ideal Dividend Dogs From 16 \"Safer\" Out Of 38 ReFa/Ro",
    "summary": "Discover high-yield investment opportunities with the ReFa/Ro Dogs strategy! Analyst forecasts suggest 19-33% net gains by June 2026.",
    "url": "https://finnhub.io/api/news?id=2bcae9a6664042c3421b6d73c4ee91e3dbff35b29551fee154f09b229d53d525",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751978201,
      "headline": "June Readers Tagged 13 Ideal Dividend Dogs From 16 \"Safer\" Out Of 38 ReFa/Ro",
      "id": 135810586,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185163643/image_185163643.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover high-yield investment opportunities with the ReFa/Ro Dogs strategy! Analyst forecasts suggest 19-33% net gains by June 2026.",
      "url": "https://finnhub.io/api/news?id=2bcae9a6664042c3421b6d73c4ee91e3dbff35b29551fee154f09b229d53d525"
    }
  },
  {
    "ts": null,
    "headline": "Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading",
    "summary": "The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.S. leads in market share due to its robust healthcare system. Schizophrenia Market Schizophrenia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Schizophrenia Market Report and Forecast 2025-203",
    "url": "https://finnhub.io/api/news?id=c10c9f7ec1a928a4f3710c0f4cce26ca1b02faf7c2e177ae419202b4780a48d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751975340,
      "headline": "Schizophrenia Market Research and Forecast Report 2025-2034 | Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading",
      "id": 135805005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.S. leads in market share due to its robust healthcare system. Schizophrenia Market Schizophrenia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The \"Schizophrenia Market Report and Forecast 2025-203",
      "url": "https://finnhub.io/api/news?id=c10c9f7ec1a928a4f3710c0f4cce26ca1b02faf7c2e177ae419202b4780a48d7"
    }
  }
]